- Home
- CLPR vs SRTS Comparison
CLPR vs SRTS Comparison
Compare CLPR & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | SRTS |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 67.5M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CLPR | SRTS |
|---|---|---|
| Price | $3.75 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 87.9K | ★ 95.6K |
| Earning Date | 02-13-2026 | 02-04-2026 |
| Dividend Yield | ★ 10.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,179,000.00 | $35,609,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.90 | N/A |
| 52 Week Low | $3.31 | $3.03 |
| 52 Week High | $5.16 | $9.08 |
Technical Indicators
Market Signals| Indicator | CLPR | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 70.09 |
| Support Level | $3.55 | $4.87 |
| Resistance Level | $3.80 | $5.49 |
| Average True Range (ATR) | 0.18 | 0.36 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 60.98 | 85.33 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.